Patents by Inventor John Lowe

John Lowe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
    Patent number: 10421756
    Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I) or any one of Compounds 100-175) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: September 24, 2019
    Assignee: Rodin Therapeutics, Inc.
    Inventors: Martin R. Jefson, John A. Lowe, III, Fabian Dey, Andreas Bergmann, Andreas Schoop
  • POTASSIUM CHANNEL MODULATORS
    Publication number: 20190218200
    Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.
    Type: Application
    Filed: June 2, 2017
    Publication date: July 18, 2019
    Inventors: Birgitte Langer Eriksen, Magnus Gustafsson, Charlotte Hougaard, Thomas Amos Jacobsen, Martin R. Jefson, Gregg F. Keaney, Jessica Klein, Janus Schreiber Larsen, John A. Lowe, III, John M. McCall, Dorte Strøbæk, Nadia Lybøl von Schoubye
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10316041
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: June 11, 2019
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10273239
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: April 30, 2019
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10253032
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: April 9, 2019
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • METHODS AND COMPOSITIONS COMPRISING PURIFIED RECOMBINANT POLYPEPTIDES
    Publication number: 20180291095
    Abstract: Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.
    Type: Application
    Filed: February 22, 2018
    Publication date: October 11, 2018
    Applicant: Genentech, Inc.
    Inventors: X. Christopher Yu, Saloumeh Kadkhodayan Fischer, Susan C. Fisher, John Lowe, Atia Naim, Ailen M. Sanchez, Christopher A. Teske, Martin Vanderlaan, Annamarie Amurao, Jayme Franklin, Corazon Victa
  • METHODS AND COMPOSITIONS COMPRISING PURIFIED RECOMBINANT POLYPEPTIDES
    Publication number: 20180273615
    Abstract: Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.
    Type: Application
    Filed: February 1, 2018
    Publication date: September 27, 2018
    Applicant: Genentech, Inc.
    Inventors: X. Christopher Yu, Saloumeh Kadkhodayan Fischer, Susan C. Fisher, John Lowe, Ailen M. Sanchez, Martin Vanderlaan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20180250267
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: May 2, 2018
    Publication date: September 6, 2018
    Inventors: John A. Lowe, III, M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20180250268
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: May 2, 2018
    Publication date: September 6, 2018
    Inventors: John A. Lowe, III, M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20180244680
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: May 2, 2018
    Publication date: August 30, 2018
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10052308
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: August 21, 2018
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • BICYCLIC INHIBITORS OF HISTONE DEACETYLASE
    Publication number: 20180215759
    Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).
    Type: Application
    Filed: March 23, 2018
    Publication date: August 2, 2018
    Inventors: Nathan Oliver Fuller, John A. Lowe, III
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20180215767
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: March 28, 2018
    Publication date: August 2, 2018
    Inventors: John A. Lowe, III, M. Amin Khan
  • HETEROBICYCLIC N-AMINOPHENYL-AMIDES AS INHIBITORS OF HISTONE DEACETYLASE
    Publication number: 20180194760
    Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I) or any one of Compounds 100-175) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.
    Type: Application
    Filed: July 5, 2016
    Publication date: July 12, 2018
    Inventors: Martin R. JEFSON, John A. LOWE, III, Fabian DEY, Andreas BERGMANN, Andreas SCHOOP
  • HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE
    Publication number: 20180194769
    Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.
    Type: Application
    Filed: July 5, 2016
    Publication date: July 12, 2018
    Inventors: Martin R. Jefson, John A. Lowe, III, Fabian Dey, Andreas Bergmann, Andreas Schoop, Nathan Oliver Fuller
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20180179217
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: August 2, 2017
    Publication date: June 28, 2018
    Inventors: John A. Lowe, III, M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20180179218
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: August 8, 2017
    Publication date: June 28, 2018
    Inventors: John A. Lowe, III, M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20180155354
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: July 19, 2017
    Publication date: June 7, 2018
    Inventors: John A. Lowe, III, M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20180127430
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: June 16, 2017
    Publication date: May 10, 2018
    Inventors: John A. Lowe, III, M. Arnin Khan
  • Bicyclic inhibitors of histone deacetylase
    Patent number: 9951069
    Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: April 24, 2018
    Assignee: Rodin Therapeutics, Inc.
    Inventors: Nathan Oliver Fuller, John A. Lowe, II